Introduction
Rearrangements in the anaplastic lymphoma kinase (
ALK) gene occur in 3–7% of patients with non-small cell lung cancer (NSCLC) (Shaw et al.
2009), and ALK-positive lung cancer has been defined as a distinct clinical and molecular subtype of NSCLC (Lin et al.
2017; Shaw et al.
2009; Soda et al.
2007). NSCLCs harboring
ALK rearrangements are ALK-dependent for growth and survival, and show marked sensitivity to treatment with ALK tyrosine kinase inhibitors (TKIs), such as crizotinib (Shaw et al.
2013; Solomon et al.
2014), ceritinib (Shaw et al.
2017; Soria et al.
2017), and alectinib (Novello et al.
2018; Peters et al.
2017). Thus, according to recent clinical trials, ALK-positive lung cancer could be considered as the best subgroup in advanced-stage NSCLCs, showing good long-term survival when ALK TKIs are given as first-line treatment and continue to subsequent treatment (Peters et al.
2017; Solomon et al.
2018). Therefore, routine testing for
ALK gene rearrangement is recommend in all patients with non-squamous NSCLC (Hanna et al.
2017; Non-small cell lung cancer (Version 6.2018)
2018; Planchard et al.
2018).
Fluorescence in situ hybridization (FISH) using tissue biopsy specimens is the gold standard for the detection and confirmation of
ALK rearrangement by break-apart assay, which yields signals for the fusion
ALK gene. Immunohistochemistry (IHC) is widely used and also FDA-approved diagnostic test to identify ALK protein, and correlation between positive ALK IHC and a positive
ALK-FISH is over 90% in general (Kerr and Lopez-Rios
2016; Lindeman et al.
2018). However, this method often is not repeatable due to difficulties in the acquisition of tumor tissues (Kerr and Lopez-Rios
2016). In addition, rebiopsy and analysis of acquired mutations within the ALK tyrosine kinase domain have been highlighted in patients who relapsed after first-line ALK TKI treatment in the era of next-generation ALK TKIs (Dagogo-Jack et al.
2018; Gainor et al.
2016; Lin et al.
2017). Blood-based liquid biopsy using reverse-transcription polymerase chain reaction (RT-PCR) is expected to overcome these limitations and may permit frequent assessment with monitoring of biomarkers (Nilsson et al.
2016; Perez-Callejo et al.
2016). Several reports have described liquid biopsy for the detection of
ALK rearrangement (Ilie et al.
2012; Li et al.
2017; Nilsson et al.
2016; Pailler et al.
2013; Rolfo et al.
2017). Among the sources of blood-based liquid biopsy, platelets have been shown to provide valuable information regarding the tumor by sequestering RNA released as circulating microvesicles from the tumor. Moreover, platelets can be immediately isolated and can undergo repetitive examinations for serial monitoring of biomarkers using RT-PCR (Best et al.
2015; Nilsson et al.
2011; Nilsson et al.
2016).
However, although liquid biopsy has many advantages compared with tissue biopsy, there are several limitations with regard to the application of blood-based liquid biopsy in ALK-positive NSCLC. In fact, detection techniques have not been standardized according to the sources of liquid biopsy, and commercial kits for routine use of liquid specimens, particularly by RT-PCR, are limited, unlike the situation in the detection of epidermal growth factor receptor (
EGFR) activating and resistance mutations. Recently, next-generation sequencing (NGS) using a commercial platform for liquid biopsy has expanded the scope of applications for the detection of acquired mutations and for diagnosis in ALK-positive NSCLC (Beadling et al.
2016; Cui et al.
2017; Gainor et al.
2016; Lin et al.
2017; Nilsson et al.
2016; Rolfo et al.
2017; Wang et al.
2016; Yoda and Lin
2018). However, the wide application of liquid NGS is limited owing to the need for specialized equipment and the high costs of the method.
In this study, we aimed to assess the feasibility of blood-based liquid biopsy using plasma and platelets for detection of ALK rearrangement by RT-PCR with commercial kits initially developed for tissue genotyping. In addition, we investigated the clinical characteristics of patients according to the positivity of liquid biopsy and the predictive value of blood-based liquid biopsy for ALK inhibitor treatment.
Discussion
In this study, we investigated the feasibility of blood-based liquid biopsy for the detection of ALK rearrangement and its predictive value for ALK inhibitor treatment. Liquid biopsy using plasma and platelets had favorable sensitivity compared with FISH assays for tumor tissues, and delayed blood sampling, since diagnosis showed higher positivity for liquid biopsy. In addition, platelets could predict the treatment outcome of ALK inhibitors more precisely than plasma.
Blood-based liquid biopsy is minimally invasive, easily repeatable method, and may predict acquisition of resistance by serial monitoring earlier than radiologic progression or the appearance of clinical symptoms. However, recent guidelines for liquid biopsy refer only to a limited subset of ALK-positive NSCLC (Merker et al.
2018; Rolfo et al.
2018). PCR-based methods are not recommended for routine use for
ALK rearrangement detection from circulating tumor DNA (ctDNA). Platelet- or circulating tumor cell (CTC)-derived RNA may be useful; however, validation with a prospective cohort is necessary (Rolfo et al.
2018). This could be a problem owing to the source of liquid biopsy and the detection platform. The detection of CTCs is not routinely performed, and the technique has not been standardized. Circulating-free DNA requires extensive deep sequencing of genomic DNA for detection of the chromosomal break-point (Nilsson et al.
2016). Moreover, standardized methods for the isolation and analysis of extracellular vesicles are also needed (Sáenz-Cuesta et al.
2015). Digital-droplet PCR (ddPCR), BEAMing, and NGS have been reported to have promising sensitivity in the detection of
ALK rearrangement, although there are still barriers for their use in daily practice.
Plasma and platelets have advantages in terms of easy isolation and smooth application to real practice, although they are not routinely isolated in clinics. In addition, RT-PCR can facilitate easy access, rapid readout, repeated examination, and satisfactory costs. In the present study, liquid biopsy using plasma and platelets analyzed by RT-PCR showed favorable performance in the detection of
ALK rearrangement. In particular, platelets showed slightly higher sensitivity in detection and superior predictability of treatment outcomes than plasma. In addition, platelets showed better performance in the graph of Ct analysis than plasma. That is, platelets could better reflect the molecular status of tumor tissue than plasma, although there were no differences in total amount of extracted RNA between plasma and platelets. In several reports, platelets were found to contain the genetic components of primary tumors and metastatic lesions by uptake of tumor-derived RNA as a form of microvesicles, and it may be possible to provide more information on the tumor, suggesting the presence of tumor-educated platelets (Best et al.
2015; Joosse and Pantel
2015; Nilsson et al.
2016). However, the number of patients positive for liquid biopsy included in present study is small (
n = 26), and those patients received crizotinib in different lines of treatment. Thus, a multivariate analysis in a large cohort of patients is needed to confirm a predictive power of ALK positivity in platelets for ALK inhibitor treatment.
However, the results of this study that patients positive for genetic alterations (ALK rearrangements) in blood component (platelets) had a better prognosis to targeted therapy (ALK TKI) are not typical findings compared with previous studies, especially for EGFR mutation. There may be two speculations for that result: one is that the phenomenon could be specific for ALK-positive lung cancer, and the other is that cases with FISH-positive in tissue and ALK-negative in platelets were false positives of tissue FISH assay. Thus, prospective collection of tissue specimen and further investigation with large numbers of cases would be in need.
In a previous study, plasma RNA showed lower sensitivity than platelets for the detection of
ALK rearrangement by RT-PCR, and the authors speculated that rapid degradation of free-circulating RNA or lack of free-circulating exosomes containing
ALK rearrangement may be the cause (Nilsson et al.
2016). In contrast, in the present study, plasma showed almost equivalent performance to platelets for detection, and the combination of positive results for plasma and platelets had synergistic effects on increased sensitivity. This may be attributed to the efforts for precise control of quality in pre-analytical parameters, such as appropriate tubes to collect blood, short delay for transfer to laboratory procedures (within 2 h from venous sampling), established centrifugation protocols, and storage of samples in a freezer. Thus, plasma and platelets may have applications in liquid biopsy for the detection of
ALK rearrangement. Despite these advantages, however, several factors can influence the RNA profiles, including platelet counts, extent of cancer dissemination, amount of blood collection, systemic inflammation, and cardiovascular events (Joosse and Pantel
2015).
We found that the subgroup of delayed blood sampling since diagnosis showed higher positivity for liquid biopsy. This difference may be related to the observation that most blood sampling was performed after initiation of systemic treatment and that various treatment modalities were introduced before crizotinib treatment. Thus, although the small number of samples at the time of diagnosis could not be ignored, an assumption that the load of ALK rearrangement increased in patients who have not been treated effectively with ALK inhibitors may be reasonable. In fact, the result of liquid biopsy using platelets showed more negativity when the patients were treated with ALK TKI rather than chemotherapy. Therefore, liquid biopsy can facilitate the diagnosis of ALK-rearranged NSCLC as a supplement to tissue biopsy, and the detection rate and utility of liquid biopsy could be higher in the later period or at progression than in the initial period since diagnosis. However, to validate sensitivity of ALK liquid biopsy as a screening tool at diagnosis, analyzing only the samples collected before ALK TKI therapy may be warranted.
In the present study, serial monitoring using liquid biopsy showed that the analysis results were correlated with the therapeutic response to ALK inhibitors, as determined by imaging analysis, and a positive result was observed prior to true radiologic progression. This suggested that RNA released into the blood by free form (plasma) or loading in microvesicles (platelets) could function as a communicator between tumor cells and their microenvironment or distant metastasis. In addition, these findings supported that blood-based analysis could be used to monitor the ongoing alterations in tumors and predict disease progression, allowing for earlier adjustment of the treatment approach. Indeed, according to recent studies, liquid biopsy may have clinical value for the management of patients with ALK-positive NSCLC in the near future (Dagogo-Jack et al.
2018; Yoda and Lin
2018). This method could also be used to detect acquired resistance mutations from ctDNA in the setting of progression after first-line ALK TKI treatment, representing the clonal evolution of acquired mutations, and guiding the selection of subsequent ALK inhibitors. However, no studies have evaluated PCR-based platforms for resistance mutations in ALK-positive NSCLC. According to a recent guideline for liquid biopsy, an NGS panel using ctDNA is preferred for detection of
ALK acquired resistance mutations when rebiopsy of the progression site is not feasible (Rolfo et al.
2018). Thus, prospective validation studies using RT-PCR may be warranted as a time-saving strategy for identification of mutation-specific inhibitory characteristics to facilitate the application of ALK inhibitors.
There were several limitations to this study. First, prospective sample collection was performed only for some samples. The number of samples at the time of diagnosis was not sufficient, and a prospective validation study needs to be performed to identify the role of ALK liquid biopsy in initial screening. Second, the total extracted amount of RNA from plasma and platelets was much lower than that from FFPE tissues. This could have been related to variations in tumor characteristics (i.e., shedding or non-shedding) as well as patient factors. Although direct application of the liquid source to a tissue-based kit showed favorable performance in this study, novel, more sensitive platforms for liquid-based PCR or high-end detection methods, such as ddPCR or NGS, are needed for screening and acquired mutation detection in ALK-positive NSCLC. Third, quantification of the results of RT-PCR was not performed, and such results may be crucial for predicting true progression during longitudinal monitoring. Finally, the results of genotyping for
EML4-
ALK fusion variants were not presented in this article. In recent studies,
ALK variant status was found to affect the efficacy of ALK inhibitors, survival, and development of specific resistance mutations (e.g., variant 3 for G1202R mutation) (Lin et al.
2018; Woo et al.
2017; Yoshida et al.
2016). Indeed, we performed liquid-based genotyping for
ALK variants using a co-developed tissue-based genotyping kit, but failed to derive meaningful data due to the high rates of invalid results (plasma, 46.8%; platelets, 53.4%; data not shown in tables). Further prospective validation studies with sensitive detection methods or other sources of liquid biopsy are necessary.
In conclusion, plasma and platelets are valuable and complementary sources for liquid biopsy in the detection of ALK rearrangements and showed favorable sensitivity, despite using a tissue-based RT-PCR kit. Liquid biopsy may have a supplementary role in the diagnosis of ALK-positive NSCLC, particularly during the later period after diagnosis, and platelets may be useful for predicting treatment outcomes of ALK inhibitors.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.